<?xml version="1.0" encoding="UTF-8"?>
<p>The production of a SARS-CoV-2 vaccine has met major obstacles since the beginning such as the absence of clear data on the immune response elicited by SARS-CoV-2 and the notable side effects observed in SARS-CoV and MERS vaccine candidates (
 <xref rid="B12" ref-type="bibr">Bolles et al., 2011</xref>; 
 <xref rid="B96" ref-type="bibr">Tseng et al., 2012</xref>; 
 <xref rid="B3" ref-type="bibr">Agrawal et al., 2016</xref>). Additionally, a decreasing confidence of the general population in the vaccination effort can become a major obstacle for the development of a efficient vaccination programme.
</p>
